{"schema_version":"secwatch.filing_event.v1","accession":"0001390478-24-000016","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.876454+00:00","generated_at":"2026-05-31T09:38:50.368581+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SELLAS Life Sciences Q2 2024 net loss $7.5M; cash $9.1M; $21M capital raise; IDMC supports REGAL","bullets":["Net loss $7.5M ($0.13/share) vs $8.8M ($0.31/share) in Q2 2023; R&D expenses $5.2M.","Cash $9.1M at June 30; subsequent $21M gross proceeds from premium-priced registered direct offering.","IDMC recommends continue Phase 3 REGAL (GPS) in AML without modifications; interim analysis expected by Q4 2024.","Phase 2a SLS009 in r/r AML: ORR 33% (60mg QW), 50% (30mg BIW), 100% in ASXL1 mutant cohort."],"urls":{"canonical":"https://secwatch.observer/filing/0001390478-24-000016","json":"https://secwatch.observer/filing/0001390478-24-000016.json","markdown":"https://secwatch.observer/filing/0001390478-24-000016.md","text":"https://secwatch.observer/filing/0001390478-24-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000139047824000016/0001390478-24-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000139047824000016/sls-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:38:50.368581+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}